Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9AA | ISIN: US75943R1023 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
3,355 US-Dollar
+3,87 % +0,125
1-Jahres-Chart
RELAY THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
RELAY THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur RELAY THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiRelay Therapeutics, Inc. - 8-K, Current Report1
DiCitizens JMP maintains Relay Therapeutics stock rating after trial data2
DiCitizens JMP hält an Bewertung für Relay Therapeutics nach Studiendaten fest4
MoRelay Therapeutics reports promising breast cancer drug data1
MoRelay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025120Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support...
► Artikel lesen
RELAY THERAPEUTICS Aktie jetzt für 0€ handeln
08.05.Relay Therapeutics, Inc. (RLAY): A Bull Case Theory7
05.05.Relay Therapeutics, Inc. - 10-Q, Quarterly Report4
05.05.Relay Therapeutics, Inc.: Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates339Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to...
► Artikel lesen
05.05.Relay Therapeutics GAAP EPS of -$0.46 beats by $0.03, revenue of $7.68M beats by $7.67M5
05.05.Relay Therapeutics, Inc. - 8-K, Current Report1
28.04.Relay Therapeutics, Inc.: Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 20255
04.04.Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers8
28.02.Relay Therapeutics stock target cut to $12 at Citizens JMP13
26.02.Relay Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Relay Therapeutics, Inc. - 10-K, Annual Report1
26.02.Relay Therapeutics, Inc. - 8-K, Current Report-
25.02.Relay Therapeutics Q4 2024 Earnings Preview3
19.02.Relay Therapeutics, Inc.: Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 202533
24.01.Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays' $17 Price Target25
13.01.Relay Therapeutics, Inc. - 8-K, Current Report-
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1